Contineum Therapeutics Reports Positive Phase 1b Chronic Pain Data

Contineum Therapeutics, Inc. Class A ( (CTNM) ) has issued an update.

On April 30, 2026, Contineum Therapeutics reported positive topline results from an exploratory Phase 1b trial of its non-opioid candidate PIPE-791 in patients with chronic osteoarthritis pain and chronic low back pain. PIPE-791, given orally at 10 mg once daily in a four-week randomized, double-blind, placebo-controlled crossover study of 43 patients, met its primary objective by showing a favorable safety and tolerability profile, with only mild to moderate adverse events and no serious safety signals.

Exploratory efficacy analyses using the pain-intensity numerical rating scale showed that PIPE-791 generally delivered greater numerical reductions in both average and worst daily pain than placebo, with additional measures such as responder rates and functional scores reinforcing these trends. The results mark the largest and longest PIPE-791 chronic pain study to date, and the company said the data, particularly in osteoarthritis pain, provide preliminary evidence of efficacy that supports continued clinical development and may strengthen its positioning in the search for non-opioid chronic pain treatments.

The most recent analyst rating on (CTNM) stock is a Hold with a $14.00 price target. To see the full list of analyst forecasts on Contineum Therapeutics, Inc. Class A stock, see the CTNM Stock Forecast page.

Spark’s Take on CTNM Stock

According to Spark, TipRanks’ AI Analyst, CTNM is a Neutral.

The score is held back primarily by weak financial performance (no recurring revenue, widening losses, and rising cash burn), partially offset by a stronger balance sheet and liquidity runway. Technical signals are mixed but not bearish, while valuation is difficult to anchor due to negative earnings and no dividend. Corporate updates support long-term execution potential but introduce dilution risk via the expanded ATM.

To see Spark’s full report on CTNM stock, click here.

More about Contineum Therapeutics, Inc. Class A

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapies for neuroscience, inflammation and immunology indications with significant unmet medical need. Its pipeline includes PIPE-791, an LPA1 receptor antagonist in development for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being studied in multiple sclerosis and major depressive disorder.

Average Trading Volume: 279,470

Technical Sentiment Signal: Buy

Current Market Cap: $466.6M

Learn more about CTNM stock on TipRanks’ Stock Analysis page.